161.56+0.31+0.19%
10:07:24 AMNYSE
Plus500. 81% of retail CFD accounts lose money
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
Is Johnson & Johnson stock a Buy, Sell or Hold?
Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 43 buy ratings, 34 hold ratings, and 1 sell ratings.What was the 52-week low for Johnson & Johnson stock?
The low in the last 52 weeks of Johnson & Johnson stock was 144.95. According to the current price, Johnson & Johnson is 111.46% away from the 52-week low.What was the 52-week high for Johnson & Johnson stock?
The high in the last 52 weeks of Johnson & Johnson stock was 175.96. According to the current price, Johnson & Johnson is 91.82% away from the 52-week high.What are analysts forecasts for Johnson & Johnson stock?
The 78 analysts offering price forecasts for Johnson & Johnson have a median target of 185.35, with a high estimate of 215.00 and a low estimate of 40.00. The median estimate represents a 87.17 difference from the last price of 161.56.Johnson & Johnson Stock Snapshot
0.00
Bid
0.00
Bid Size
0.00
Ask
0.00
Ask Size
3/12/2024
See Also
Johnson & Johnson (JNJ) Stock Price | Stock Quote Nyse - MarketScreenerJ&J Snack Foods Corp. (JJSF) Stock Price, Quote & News - Stock AnalysisDate
10:07 AM
Time
0.00
Volume
161.25
Prev. Close
161.55
Open
384.28 B
Market Cap
2.41 B
Number of Shares
161.13
Day Low
162.38
Day High
161.56
144.95
52 Week Low
175.96
52 Week High
161.56
4.80
Dividend
2.98
Dividend Yield
15.80
P/E Ratio
99.84
Free Float in %
33.74
Book Value per Share
11.23
Cash Flow per Share
Johnson & Johnson NewsMore News
InvestorPlace
3 Must-Have Dividend Kings for a Steady Income Stream
Seeking Alpha
J&J submits sBLA for Tremfya for ulcerative colitis
InvestorPlace
The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns
Seeking Alpha
Cantor sees strong year ahead for oncology M&A
Historical Prices for Johnson & Johnson
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Johnson & Johnson Analyst Data
Total Analysts: 78
Buy Ratings: 43 Neutral Ratings: 34 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 40.00 Median: 185.35 Highest: 215.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Johnson & Johnson Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 02/28/24 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 02/20/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 02/06/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/24/24 | Morgan Stanley | Maintained Hold | $169 | neutral | ||
| 01/24/24 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 01/23/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/09/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/03/24 | Raymond James Financial, Inc. | Maintained Buy | $175 | gut | ||
| 12/13/23 | Wells Fargo & Co | Downgraded to Hold | $163 | neutral | ||
| 12/06/23 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 12/01/23 | RBC Capital Markets | Maintained Buy | $178 | gut | ||
| 12/01/23 | UBS | Upgraded to Buy | $180 | gut | ||
| 11/20/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 11/17/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/23/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/18/23 | Morgan Stanley | Maintained Hold | $171 | neutral | ||
| 10/18/23 | Raymond James Financial, Inc. | Maintained Buy | $172 | gut | ||
| 10/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/12/23 | Barclays Capital | Maintained Hold | $162 | neutral | ||
| 10/11/23 | Morgan Stanley | Maintained Hold | $174 | neutral | ||
| 10/09/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/05/23 | RBC Capital Markets | Maintained Buy | $178 | gut | ||
| 10/02/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/08/23 | Barclays Capital | Maintained Hold | $158 | neutral | ||
| 09/06/23 | HSBC | Maintained Sell | $175 | schlecht | ||
| 09/05/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/05/23 | Raymond James Financial, Inc. | Maintained Buy | $179 | gut | ||
| 08/31/23 | Wells Fargo & Co | Maintained Buy | $186 | gut | ||
| 08/31/23 | Morgan Stanley | Maintained Hold | $172 | neutral | ||
| 08/30/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 08/22/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 08/04/23 | Atlantic Equities | Maintained Hold | $170 | neutral | ||
| 07/31/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 07/25/23 | Barclays Capital | Maintained Hold | $175 | neutral | ||
| 07/24/23 | Raymond James Financial, Inc. | Maintained Buy | $184 | gut | ||
| 07/21/23 | J.P. Morgan | Maintained Hold | $180 | neutral | ||
| 07/21/23 | Morgan Stanley | Maintained Hold | $187 | neutral | ||
| 07/21/23 | Credit Suisse | Maintained Hold | $175 | neutral | ||
| 07/13/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 07/11/23 | Morgan Stanley | Maintained Hold | $187 | neutral | ||
| 06/07/23 | Mizuho | Maintained Buy | $40 | gut | ||
| 05/30/23 | Citigroup Corp. | Maintained Buy | $185 | gut | ||
| 04/19/23 | Atlantic Equities | Maintained Hold | $167 | neutral | ||
| 04/19/23 | Morgan Stanley | Maintained Hold | $183 | neutral | ||
| 04/19/23 | Raymond James Financial, Inc. | Maintained Buy | $181 | gut | ||
| 04/10/23 | Morgan Stanley | Maintained Hold | $179 | neutral | ||
| 03/29/23 | UBS | Maintained Hold | $164 | neutral | ||
| 03/01/23 | Guggenheim | Maintained Hold | $161 | neutral | ||
| 02/01/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut |
Johnson & Johnson Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 88,398 | 90,811 | 93,706 | 96,768 | 102,564 |
| Dividend | 4.80 | 5.00 | - | - | 6.44 |
| Dividend Yield (in %) | 2.98 % | 3.11 % | 3.15 % | 3.48 % | 4.00 % |
| EPS | - | 11.00 | 11.42 | 11.70 | 12.34 |
| P/E Ratio | 15.15 | 14.64 | 14.10 | 13.76 | 13.05 |
| EBIT | 29,152 | 30,156 | 31,262 | 31,994 | 34,146 |
| EBITDA | 33,433 | 34,832 | 36,855 | 38,949 | 38,137 |
| Net Profit | 25,944 | 26,784 | 27,552 | 28,044 | 29,567 |
| Net Profit Adjusted | 25,944 | 26,784 | 27,552 | 28,044 | 29,567 |
| Pre-Tax Profit | 30,997 | 31,951 | 32,923 | 33,579 | 35,448 |
| Net Profit (Adjusted) | - | - | 25,233 | 26,575 | 27,528 |
| EPS (Non-GAAP) ex. SOE | 10.68 | 11.21 | 9.49 | - | - |
| EPS (GAAP) | 8.60 | 9.04 | - | 9.68 | 10.03 |
| Gross Income | 65,953 | - | 70,614 | 74,601 | 78,462 |
| Cash Flow from Investing | - | - | - | - | -6,280 |
| Cash Flow from Operations | - | - | - | - | 31,654 |
| Cash Flow from Financing | - | - | - | - | -20,244 |
| Cash Flow per Share | 11.23 | 11.72 | 12.47 | - | - |
| Free Cash Flow | - | 24,525 | 24,996 | 26,410 | 29,358 |
| Free Cash Flow per Share | 10.79 | 9.96 | 9.27 | - | - |
| Book Value per Share | 33.74 | 37.11 | - | 36.05 | 37.59 |
| Net Debt | -2,998 | -10,383 | -14,698 | -31,584 | - |
| Research & Development Exp. | 14,968 | 15,336 | 15,786 | 16,329 | 17,106 |
| Capital Expenditure | - | 4,073 | - | - | 3,780 |
| Selling, General & Admin. Exp. | - | 22,334 | 23,032 | 23,918 | 24,955 |
| Shareholder’s Equity | - | - | - | - | 112,208 |
| Total Assets | - | - | - | - | 227,766 |
| Previous Quarter ending 12/31/23 | Current Quarter ending 03/31/24 | Next Quarter ending 06/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 15 | 16 | 16 | 16 | 13 |
| Average Estimate | 2.281 USD | 2.635 USD | 2.729 USD | 10.998 USD | 11.417 USD |
| Year Ago | 2.350 USD | 2.680 USD | 2.800 USD | - | 10.998 USD |
| Publish Date | 1/23/2024 | 4/16/2024 | 7/16/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 15 | 14 | 14 | 18 | 18 |
| Average Estimate | 21,022 USD | 21,457 USD | 22,359 USD | 88,398 USD | 90,811 USD |
| Year Ago | 23,706 USD | 24,746 USD | 25,530 USD | 85,159 USD | 88,398 USD |
| Publish Date | 1/23/2024 | 4/16/2024 | 7/16/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Johnson & Johnson Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Taubert Jennifer L | 02/12/2024 | 666.00 | 154,851.00 | 157.85 | Sell | No |
| Wolk Joseph J | 02/12/2024 | 773.00 | 68,890.00 | 157.85 | Sell | No |
| Forminard Elizabeth | 02/12/2024 | 236.00 | 8,340.00 | 157.85 | Sell | No |
| Decker Robert J | 02/12/2024 | 86.00 | 18,973.00 | 157.85 | Sell | No |
| Wengel Kathryn E | 02/12/2024 | 333.00 | 82,265.87 | 157.85 | Sell | No |
| Taubert Jennifer L | 02/12/2024 | 1,302.00 | 155,517.00 | n/a | Buy | No |
| Forminard Elizabeth | 02/12/2024 | 651.00 | 8,576.00 | n/a | Buy | No |
| Wolk Joseph J | 02/12/2024 | 1,780.00 | 69,663.00 | n/a | Buy | No |
| Decker Robert J | 02/12/2024 | 313.00 | 19,059.00 | n/a | Buy | No |
| Wengel Kathryn E | 02/12/2024 | 651.00 | 82,598.87 | n/a | Buy | No |
| Hait William | 02/11/2024 | 4,076.00 | 38,240.00 | 157.40 | Sell | No |
| Forminard Elizabeth | 02/11/2024 | 1,034.00 | 7,925.00 | 157.40 | Sell | No |
| Taubert Jennifer L | 02/11/2024 | 13,403.00 | 154,215.00 | 157.40 | Sell | No |
| Schmid Timothy | 02/11/2024 | 2,887.00 | 12,791.00 | 157.40 | Sell | No |
| Fasolo Peter | 02/11/2024 | 7,019.00 | 111,625.00 | 157.40 | Sell | No |
| Decker Robert J | 02/11/2024 | 523.00 | 18,746.00 | 157.40 | Sell | No |
| Swanson James D. | 02/11/2024 | 1,695.00 | 14,318.00 | 157.40 | Sell | No |
| Wolk Joseph J | 02/11/2024 | 10,816.00 | 67,883.00 | 157.40 | Sell | No |
| Duato Joaquin | 02/11/2024 | 15,900.00 | 361,339.00 | 157.40 | Sell | No |
| Broadhurst Vanessa | 02/11/2024 | 2,136.00 | 23,735.00 | 157.40 | Sell | No |
| Wengel Kathryn E | 02/11/2024 | 7,066.00 | 81,947.87 | 157.40 | Sell | No |
| Hait William | 02/11/2024 | 1,285.00 | 42,316.00 | n/a | Buy | No |
| Hait William | 02/11/2024 | 7,647.00 | 41,031.00 | n/a | Buy | No |
| Schmid Timothy | 02/11/2024 | 825.00 | 15,678.00 | n/a | Buy | No |
| Taubert Jennifer L | 02/11/2024 | 22,433.00 | 163,849.00 | n/a | Buy | No |
Johnson & Johnson Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Johnson & Johnson | 4.70 | 3.00 | USD |
| 2022 | Johnson & Johnson | 4.45 | 2.52 | USD |
| 2021 | Johnson & Johnson | 4.19 | 2.45 | USD |
| 2020 | Johnson & Johnson | 3.98 | 2.53 | USD |
| 2019 | Johnson & Johnson | 3.75 | 2.57 | USD |
| 2018 | Johnson & Johnson | 3.54 | 2.78 | USD |
| 2017 | Johnson & Johnson | 3.32 | 2.38 | USD |
| 2016 | Johnson & Johnson | 3.15 | 2.73 | USD |
| 2015 | Johnson & Johnson | 2.95 | 2.87 | USD |
| 2014 | Johnson & Johnson | 2.76 | 2.64 | USD |
| 2014 | Johnson & Johnson | 2.76 | 2.63 | USD |
| 2013 | Johnson & Johnson | 2.59 | 2.80 | USD |
| 2013 | Johnson & Johnson | 2.59 | 2.83 | USD |
| 2012 | Johnson & Johnson | 2.40 | 3.45 | USD |
| 2012 | Johnson & Johnson | 2.40 | 3.42 | USD |
| 2011 | Johnson & Johnson | 2.25 | 3.43 | USD |
| 2010 | Johnson & Johnson | 2.11 | 3.41 | USD |
| 2009 | Johnson & Johnson | 1.93 | 3.00 | USD |
| 2008 | Johnson & Johnson | 1.79 | 3.06 | USD |
| 2007 | Johnson & Johnson | 1.62 | 2.43 | USD |
| 2006 | Johnson & Johnson | 1.46 | 2.21 | USD |
| 2005 | Johnson & Johnson | 1.27 | 2.11 | USD |
| 2004 | Johnson & Johnson | 1.09 | 1.72 | USD |
| 2003 | Johnson & Johnson | 0.92 | 1.82 | USD |
| 2002 | Johnson & Johnson | 0.79 | 1.47 | USD |
| 2001 | Johnson & Johnson | 0.70 | 1.17 | USD |
| 2000 | Johnson & Johnson | 0.62 | 1.18 | USD |
| 1999 | Johnson & Johnson | 0.55 | 1.18 | USD |
*Yield of the Respective Date
Johnson & Johnson Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.635 USD | Q1 2024 Earnings Release | 04/16/2024 |
| Earnings Report | 2.729 USD | Q2 2024 Earnings Release | 07/16/2024 |
| Earnings Report | - | Q3 2024 Earnings Release | 10/15/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 01/28/2025 |
Johnson & Johnson Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 2.290 USD | Q4 2023 Earnings Release | 01/23/2024 |
| Press Conference | - | - | 01/23/2024 |
| Press Conference | - | - | 10/17/2023 |
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Johnson & Johnson Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.84 |
| The Vanguard Group, Inc. | 9.52 |
| Vanguard Group, Inc. (Subfiler) | 9.10 |
| SSgA Funds Management, Inc. | 5.52 |
| State Street Corp. | 5.52 |
| Vanguard Total Stock Market ETF | 3.14 |
| BlackRock Fund Advisors | 2.89 |
| Vanguard 500 Index Fund | 2.47 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| Geode Capital Management LLC | 2.13 |
| State Farm Investment Management Corp. | 1.32 |
| Capital Research & Management Co. (International Investors) | 1.20 |
| Fidelity 500 Index Fund | 1.19 |
| SPDR S&P 500 ETF Trust | 1.17 |
| Norges Bank (13F) | 1.08 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Johnson & Johnson Management
| Name | Job |
|---|---|
| Joaquin Duato | Chairman & Chief Executive Officer |
| Robert J. Decker | Chief Accounting Officer & Controller |
| Ronald A. Kapusta | Chief Accounting Officer & Controller |
| Frederic H. Moll | Chief Development Officer |
| William N. Hait | Chief External Innovation & Executive VP-Medical |
| Joseph J. Wolk | Chief Financial Officer & Executive Vice President |
| Paul Ruh | Chief Financial Officer-Consumer Health |
| Peter M. Fasolo | Chief Human Resources Officer & Executive VP |
| James D. Swanson | Chief Information Officer & Executive VP |
| Kathryn E. Wengel | Chief Technical Operations & Risk Officer |
| Jonathan Sheh | Director-Workplace Experience |
| Jennifer L. Taubert | EVP & Worldwide Chairman-Innovative Medicine |
| Elizabeth Forminard | Executive Vice President & General Counsel |
| Michael Bzdak | Global Dir-Employee Engagement-Global Cmnty Impact |
| George Davy | Global HR Director |
| Caroline Tillett | Global Head-Consumer Health |
| Ahmet Tezel | Global Head-Research & Development |
| Kathleen M. Widmer | Group Chairman-Consumer North America |
| Neil Ackerman | Head-Innovation, Global Supply & Transformation |
| Nadja Y. West | Independent Director |
| Paula A. Johnson | Independent Director |
| Hubert Joly | Independent Director |
| Marillyn A. Hewson | Independent Director |
| Eugene A. Woods | Independent Director |
| D. Scott Davis | Independent Director |
| Mark B. McClellan | Independent Director |
| Darius Adamczyk | Independent Director |
| Mary C. Beckerle | Independent Director |
| Jennifer A. Doudna | Independent Director |
| Mark Alan Weinberger | Independent Director |
| Anne M. Mulcahy | Lead Independent Director |
| Warren Foust | President-Surgical Vision |
| Marc Larkins | Secretary |
| Thomas J. Spellman | Secretary |
| Meredith Stevens | Vice President |
| Jessica Moore | Vice President-Investor Relations |
| William E. Cohn | Vice President-Medical Devices |
| Lisa Paley | Vice President-US Sales |
